(NASDAQ:NVAX) shareholders might be concerned after seeing the share price drop 15% in the last quarter. But that scarcely detracts from the really solid long term returns generated by the company ...

Shares of Novavax Inc. NVAX shed 3.02% to $9.32 Friday, on what proved to be an all-around rough trading session for the ...

Novavax (NVAX) and other vaccine developers rise as Investors react to rising flu and COVID-19 cases in the U.S. Read more ...

But the company trimmed its outlook. Is NVAX stock a sell in December 2024? Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant ...

Moderna leads vaccine rally amid rising respiratory infections, spurring investment in COVID-19, flu, and RSV solutions.

But the company trimmed its outlook. Is NVAX stock a sell in December 2024? Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced ...

The stock's fall snapped a five-day winning streak.

This post was written by Angel Smith Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its novel Matrix-M™ adjuvant, today announced that the Company granted a non- ...

Investors are weighing Nvidia's big AI plans and puzzling over Trump's tariff policy in the wait for fresh jobs data.

Shares of vaccine makers moved higher early Monday following a CDC report that the U.S. was seeing a significant uptick in ...

Investors speculated on Covid vaccine firms. Despite the seasonal strength for flu-related vaccines ending, Moderna (MRNA) ...